These include Byetta, Copaxone, Geldanamycin, Emtriva, Alimta, Taxol, and Rapamycin. But the process of translating a laboratory discovery into a drug is fraught with difficulties. There is a tremendous gap between the time of the original ... The researcher also bears the cost and risk of a project's failure, lacks expertise in navigating regulatory pathways, and management of outsourcing contracts. Allowing a dedicated drug development company to take over a project ...

Patients who have experienced Byetta dangers are invited to present their case to a lawyer, the pharmaceutical industry a free legal advice regarding the development of Byetta class action, which may in the wages of money for Byetta ...

The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions; the pace of market acceptance; or scientific, regulatory and other issues and risks inherent in the development and ...

Byetta revenues have been under pressure over the past few quarters due to pancreatitis fears associated with the use of the drug. Amylin is looking to return Byetta to growth now that it is armed with a US Food and Drug Administration ... Research and development (R&D) expenses declined to $46 million in the reported quarter from $52.8 million reported in the prior-year period. The decrease primarily reflects savings driven by the company's cost sharing agreement with ...

Manufacturing revenues also included $0.6 million related to the manufacture of polymer for Byetta once-weekly (proposed trade name: Bydureon). The candidate is co-developed by Alkermes Inc., Eli Lilly (NYSE:LLY) and Amylin ... The remaining 7% Notes were redeemed in full on July 1, 2010, at a total cost of approximately $46.4 million. Our Take. A couple of key action dates are coming up for Alkermes with the US Food and Drug Administration (FDA) scheduled to decide on ...

products, BYETTA(R) (exenatide) injection and SYMLIN(R) itraconazole oxygen free radicals (pramlintide acetate) injection, as well as the launch and commercialization of exenatide once weekly, Amylin's lead development compound. ...

These data further support the known safety profile of the exenatide molecule and are consistent with the previously reported profiles of BYDUREON and BYETTA® (exenatide) injection. “The DURATION trials not only help us understand the ...

Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop ... (iv) "Direct and Indirect Costs of Diabetes in the United States." American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed Oct. 2, 2009. ...

These data further support the known safety profile of the exenatide molecule and are consistent with the previously reported profiles of BYDUREON and BYETTA® (exenatide) injection. “The DURATION trials not only help us understand the .... Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the ...

BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com. Important Safety Information for BYETTA® ... Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development ...